secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001104659-23-129824
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance settles YUPELRI patent litigation with Accord; generic entry allowed no earlier than April 23, 2039
--------------------------------------------------------------------------------

- Settlement Agreement with Accord resolves Hatch-Waxman litigation over YUPELRI inhalation solution.
- Accord granted royalty-free license to market generic YUPELRI on or after April 23, 2039, subject to customary exceptions.
- Settlement subject to review by U.S. Department of Justice and Federal Trade Commission.
- Patent litigation continues against five other ANDA filers: Cipla, Eugia, Lupin, Mankind, and Orbicular.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923129824/0001104659-23-129824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923129824/tm2333786d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-129824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer